WHAT DRIVES US?

CHALLENGES

We are an independent and specialized consulting boutique for strategic questions, whose partners have a large network and many years of professional and consulting experience. We have built a diverse consulting portfolio, primarily focusing on the healthcare industry.

Our partner team stands for many years of experience and a consulting approach that focuses on the collaboration with our clients.

OUR EXPERTISE

TRANS­FORMATION

Our clients benefit not only from our industry expertise, but also from our project experience, which ranges from local sales strategies to post-merger integrations and global transformation programs. We always focus on developing solutions together with our clients and supporting their implementation.

CUSTOM COOPERATIONS

LEGAL EXPENDITURES:
TRANSPARENT & COST-EFFECTIVE

We cooperate with selected partners in order to offer our clients valuable supplementary services. With the solutions from our partner Quovant, our clients achieve fast and uncomplicated cost savings as they manage their legal affairs.

PERSONALITY COUNTS

BECOME PART
OF OUR TEAM

Are you looking for a fast-paced development path? Would you like to work in highly motivated teams? As we are constantly growing, we are looking for new personalities throughout the year to strengthen our team!

O&C CASE STUDY 2021 & VIRTUAL COME TOGETHER

PHARMTECH FUSION

Are you planning to start your career as a strategy consultant and do you want to learn more about the healthcare industry?

If so, we cordially invite you to our digital O&C Case Study!

Submit your CV by April 12, 2021 to recruiting@otto-company.com

RECRUITING

WE ARE HIRING

Are you interested in supporting healthcare companies to optimize their strategy? Is it your passion to implement innovative solutions reflecting clients´ needs?Then apply now and join our consulting team at O&C. We are looking for experienced strategy consultants and an interest in the healthcare industry.

PUBLICATIONS

NEWS FROM THE O&C LAB!

THE RELATIONSHIP BETWEEN R&D EXPENSES AND PIPELINE DRUGS

Which developments and trends can be identified with regard to R&D spending in the pharmaceutical industry since 2015 and how does this relate to the number of drugs in the pipeline?

Our research shows: Continuously increasing R&D spendings contrast with a reduction in the pipeline. To stay at the top, be innovative, and to meet increasing regulatory requirements, companies have to continuously optimize their R&D efforts.

CONSEQUENCES OF THE DIGITALE-VERSORGUNG-GESETZ

What is going to change for the healthcare industry as a consequence of the Digitale-Versorgung-Gesetz (DVG)?

With the DVG, the legislator specifically promotes for the first time digital innovations in medical provision – with far-reaching consequences for all stakeholders.